NCT00051844CompletedPhase 2
A Double Blind- Randomized, Placebo-controlled Study of Two Doses of Capravirine (AG1549) in Combination With Viracept and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Infected Patients Who Failed an Initial Nonnucleoside Reverse Transcriptase Inhibitor Containing Regimen
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Pfizer
- Enrollment
- 179
- Locations
- 53
- Primary Endpoint
- The primary objective was to determine whether the addition of capravirine to a regimen of VIRACEPT and 2 new nucleoside reverse transcriptase inhibitors would provide a higher virologic response rate over 48 weeks
Study Overview
Brief Summary
This is a 48 week study that is intended for HIV Infected persons whose first treatment regimen was with a nonnucleoside reverse transcriptase inhibitor (NNRTI) and who are now failing that regimen. They must be currently on their failing regimen to be eligible.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male or female at least 18 years old
- •HIV RNA level >1000 copies/mL at screening
- •CD4 >50 cells/uL at screening
- •Patient is currently taking a regimen that includes an NNRTI plus 2 NRTIs for at least 28 days and is currently failing this regimen
- •Patient has adequate hematology tests (absolute neutrophil count >1000/uL, Platelets>75,000uL, hemoglobin 9g/L)
- •Patient has adequate renal function (serum creatinine of <1.5 upper limit of normal)
- •Patient has adequate liver function (AST, ALT, and bilirubin < 2.5 upper limit of normal)
Exclusion Criteria
- •Previous use of protease inhibitors (except if patient has short duration of PI and was switched for tolerability reasons when viral load was <50 copies) This exception does not include Viracept
- •Women who are pregnant or lactating
Outcomes
Primary Outcomes
The primary objective was to determine whether the addition of capravirine to a regimen of VIRACEPT and 2 new nucleoside reverse transcriptase inhibitors would provide a higher virologic response rate over 48 weeks
when compared to a 3-drug regimen without capravirine in patients who had experienced virologic failure while on a nonnucleoside reverse transcriptase inhibitor regimen.
Secondary Outcomes
- The safety and tolerability of 2 doses of capravirine.
- The difference between 2 doses of capravirine in terms of tolerability, efficacy, and pharmacokinetics
- The relationship of HIV resistance (genotype and phenotype) to virologic response.
- The immunologic response as determined by CD4 and CD8 absolute lymphocyte counts
- The population pharmacokinetics of capravirine and VIRACEPT
- The pharmacokinetics of potential drug-drug interactions.
Investigators
Study Sites (53)
Loading locations...
Similar Trials
Completed
Phase 1
A Controlled Study of the Safety and Efficacy of Lessertia Frutescens in HIV-infected South African AdultsHIV InfectionsNCT00549523University of Missouri-Columbia133
Unknown
Phase 1
Phase Ib Study of Safety, Tolerability and Pharmacokinetics of Elpida Once Weekly in Healthy VolunteersHIV InfectionsNCT03730311Viriom24
Completed
Phase 1
Study to Assess Safety and Ability to Induce Immune Responses of HIV-1 Vaccines M3 and M4 Given Alone or in Combination in HIV-infected AdultsHIV-1 InfectionNCT03844386University of North Carolina, Chapel Hill26
Completed
Phase 2
Four-Drug Combination Treatment in Hiv-Infected Subjects Failing Therapy With Antiretroviral RegimensHIV InfectionsNCT00052117Pfizer300
Completed
Phase 2
High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAARTHIV-1 InfectionNCT01403051Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections167